Ab&B Bio-Tech Calls 2026 EGM to Overhaul Governance and Appoint New Auditor

Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ) just unveiled an update.

Ab&B Bio-Tech CO., LTD. JS has called its first extraordinary general meeting of 2026 for May 27 in Taizhou, with shareholders able to attend both on-site and via an eVoting portal. The meeting will be open to registered shareholders and their proxies, with detailed procedures set for registration, proxy submission, and virtual participation.

Shareholders will vote on abolishing the supervisory committee and making related amendments to the articles of association and internal governance policies. They will also consider appointing Ms. Lui Mei Ka as an independent non-executive director and Prism as the company’s auditors, changes that could reshape oversight structures and refresh the firm’s governance and audit frameworks.

The resolutions will be decided by poll in line with the company’s articles and Hong Kong listing rules, and results will be posted on the exchange and company websites. The structured voting and access arrangements underscore the company’s emphasis on formal governance processes and transparent disclosure to its investor base.

More about Ab&B Bio-Tech CO., LTD. JS Class H

Ab&B Bio-Tech CO., LTD. JS is a joint stock company established in the People’s Republic of China and listed in Hong Kong. The company operates in the biotech sector, with its operations based in Taizhou, Jiangsu, and is subject to Hong Kong Listing Rules and associated corporate governance requirements.

It maintains both on-site and online shareholder participation channels, reflecting a focus on accessible investor engagement and compliance with modern corporate governance standards.

Average Trading Volume: 952,807

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$11.54B

See more insights into 2627 stock on TipRanks’ Stock Analysis page.